These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 20586002

  • 21. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.
    Kajaste-Rudnitski A, Galli L, Nozza S, Tambussi G, Di Pietro A, Pellicciotta G, Monti A, Mascagni P, Moro M, Vicenzi E.
    AIDS; 2011 Jan 14; 25(2):177-83. PubMed ID: 21150561
    [Abstract] [Full Text] [Related]

  • 22. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major.
    Esposito S, D'Angelo E, Daleno C, Peia F, Scala A, Serra D, Mirra N, Galeone C, Principi N.
    Vaccine; 2010 Nov 23; 28(50):7825-8. PubMed ID: 20888873
    [Abstract] [Full Text] [Related]

  • 23. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
    El Sahly H.
    Expert Rev Vaccines; 2010 Oct 23; 9(10):1135-41. PubMed ID: 20923265
    [Abstract] [Full Text] [Related]

  • 24. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S, Tagliaferri L, Daleno C, Valzano A, Picciolli I, Tel F, Prunotto G, Serra D, Galeone C, Plebani A, Principi N.
    Vaccine; 2011 Feb 11; 29(8):1677-82. PubMed ID: 21199699
    [Abstract] [Full Text] [Related]

  • 25. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB.
    Clin Infect Dis; 2006 Nov 01; 43(9):1135-42. PubMed ID: 17029131
    [Abstract] [Full Text] [Related]

  • 26. Aflunov(®): a prepandemic influenza vaccine.
    Gasparini R, Amicizia D, Lai PL, Panatto D.
    Expert Rev Vaccines; 2012 Feb 01; 11(2):145-57. PubMed ID: 22309663
    [Abstract] [Full Text] [Related]

  • 27. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
    Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli G, Groth N, Del Giudice G.
    Hum Vaccin Immunother; 2012 Feb 01; 8(2):216-27. PubMed ID: 22426371
    [Abstract] [Full Text] [Related]

  • 28. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.
    Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U.
    Vaccine; 2011 Nov 03; 29(47):8696-704. PubMed ID: 21906647
    [Abstract] [Full Text] [Related]

  • 29. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N.
    Pediatrics; 2011 May 03; 127(5):e1161-8. PubMed ID: 21464195
    [Abstract] [Full Text] [Related]

  • 30. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.
    Faenzi E, Zedda L, Bardelli M, Spensieri F, Borgogni E, Volpini G, Buricchi F, Pasini FL, Capecchi PL, Montanaro F, Belli R, Lattanzi M, Piccirella S, Montomoli E, Ahmed SS, Rappuoli R, Del Giudice G, Finco O, Castellino F, Galli G.
    Vaccine; 2012 Jun 08; 30(27):4086-94. PubMed ID: 22521851
    [Abstract] [Full Text] [Related]

  • 31. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
    Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P.
    Clin Infect Dis; 2010 Sep 15; 51(6):668-77. PubMed ID: 20687838
    [Abstract] [Full Text] [Related]

  • 32. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.
    Banzhoff A, Haertel S, Praus M.
    Hum Vaccin; 2011 May 15; 7(5):539-48. PubMed ID: 21422814
    [Abstract] [Full Text] [Related]

  • 33. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination.
    Parretta E, Ianniello B, Ferrazin F, Rossi F, Capuano A.
    Vaccine; 2011 May 09; 29(20):3708-13. PubMed ID: 21406267
    [Abstract] [Full Text] [Related]

  • 34. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I.
    J Infect Dis; 2008 Sep 01; 198(5):642-9. PubMed ID: 18576945
    [Abstract] [Full Text] [Related]

  • 35. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, Hsieh YC, Lin TY, Huang LM.
    Vaccine; 2010 Aug 16; 28(36):5864-70. PubMed ID: 20600484
    [Abstract] [Full Text] [Related]

  • 36. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.
    Vaccine; 2008 Jul 04; 26(29-30):3640-6. PubMed ID: 18514980
    [Abstract] [Full Text] [Related]

  • 37. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.
    Vaccine; 2008 Nov 25; 26(50):6383-91. PubMed ID: 18801398
    [Abstract] [Full Text] [Related]

  • 38. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.
    Vaccine; 2010 Jan 08; 28(3):849-57. PubMed ID: 19835828
    [Abstract] [Full Text] [Related]

  • 39. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
    Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A.
    Vaccine; 2006 Apr 12; 24(16):3063-5. PubMed ID: 16464520
    [Abstract] [Full Text] [Related]

  • 40. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses.
    Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E.
    Clin Ther; 2010 Dec 12; 32(13):2186-97. PubMed ID: 21316535
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.